Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant 20 mg vs placebo in abdominally obese patients with atherogenic dyslipidemia
2005-000807-33Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherogenic dyslipidaemia (AD) and Abdominal adiposity (ABCD) comparing Rimonabant 20 mg once daily with Placebo once daily (2 arms). Started Apr 2005; status: completed.
02
Drugs
rimonabant
03
Conditions
atherogenic dyslipidaemia (AD)Abdominal adiposity (ABCD)
Beyond the preview
Go deeper on 2005-000807-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000807-33.